Tirzepatide is a next-generation dual incretin agonist that activates both the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. It has been extensively studied for its effects on appetite regulation, glycemic control, and weight management.

Each vial contains 10 mg of lyophilized Tirzepatide, produced to analytical-grade standards and supplied with bacteriostatic water for reconstitution. Research indicates that dual incretin receptor engagement can enhance metabolic efficiency beyond GLP-1–only agonists such as Semaglutide.

Research Highlights

• Dual incretin action: Activates GLP-1 and GIP pathways for synergistic metabolic response
• Metabolic support: Promotes improved insulin sensitivity and glucose regulation
• Appetite modulation: Demonstrates dose-dependent reductions in hunger and caloric intake
• Body-composition focus: Studied for reductions in adipose mass and visceral fat

Observed Outcomes in Research Settings

• Reduced appetite and delayed gastric emptying
• Progressive weight reduction over 8–12 weeks
• Improved fasting glucose and lipid markers
• Enhanced energy efficiency and satiety regulation

Dosing & Reconstitution Guide

• Reconstitution: Add 2.0 mL bacteriostatic water to the 10 mg vial → final concentration 5 mg/mL
• Measurement: Each 1 unit (0.01 mL) ≈ 50 µg
• Administration: Subcutaneous injection once weekly; rotate sites (abdomen, thigh, arm)

Suggested 8-Week Protocol (Research Reference)

*May be divided into two injections if using a 1 mL/100-unit insulin syringe.

Cycle Duration & Frequency

• Cycle length: 8–12 weeks (extend if well-tolerated)
• Frequency: Once weekly; consistent weekday recommended
• Washout: Optional 2-week clearance period after extended use

Storage Instructions

• Lyophilized: Store frozen or below 0 °C, away from light
• After reconstitution: Refrigerate at 2–8 °C; use within 30 days

What’s in the Box

• 1 × Tirzepatide 10 mg lyophilized vial
• 1 × 2 mL Bacteriostatic Water Vial for reconstitution

Safety & Frequency Note

• Limit to 1 injection per 7 days; higher frequency is not supported in research data
• Gradual escalation minimizes gastrointestinal side effects (nausea, fullness)
• Monitor for dizziness or fatigue; reduce dose if persistent

For research, analytical, and educational use only. Not for human or veterinary consumption. No therapeutic claims are made. Buyer assumes responsibility for lawful handling and use.